Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Penson

Showing results (471-480 of 570) with videos related to

Pageof 57
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2012
Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosisChunyu Li, Steven B Zeliadt, Ingrid J Hall, et al.
Urology|July 11, 2009
Access to information sources and treatment considerations among men with local stage prostate cancerScott D Ramsey, Steven B Zeliadt, Neeraj K Arora, et al.
The Journal of Urology|July 27, 2011
Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomyTodd M Morgan, Kirk A Keegan, Daniel A Barocas, et al.
BJU International|October 14, 2014
Renal cell cancer histological subtype distribution differs by race and sexLoren Lipworth, Alicia K Morgans, Todd L Edwards, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 20, 2013
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspectiveChunyu Li, Steven B Zeliadt, Ingrid J Hall, et al.
Future Oncology (London, England)|August 17, 2016
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and researchDavid F Penson, Daniel W Lin, Lawrence Karsh, et al.
The American Journal of Managed Care|May 12, 2010
Preliminary treatment considerations among men with newly diagnosed prostate cancerSteven B Zeliadt, Carol M Moinpour, David K Blough, et al.
Cancer|December 17, 2013
Racial variation in the quality of surgical care for bladder cancerDaniel A Barocas, Joann Alvarez, Tatsuki Koyama, et al.
BMC Urology|September 8, 2018
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
BMC Urology|October 5, 2018
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
Pageof 57

Showing results (471-480 of 570) with videos related to

Sort By:
Pageof 57
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2012
Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosisChunyu Li, Steven B Zeliadt, Ingrid J Hall, et al.
Urology|July 11, 2009
Access to information sources and treatment considerations among men with local stage prostate cancerScott D Ramsey, Steven B Zeliadt, Neeraj K Arora, et al.
The Journal of Urology|July 27, 2011
Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomyTodd M Morgan, Kirk A Keegan, Daniel A Barocas, et al.
BJU International|October 14, 2014
Renal cell cancer histological subtype distribution differs by race and sexLoren Lipworth, Alicia K Morgans, Todd L Edwards, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 20, 2013
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspectiveChunyu Li, Steven B Zeliadt, Ingrid J Hall, et al.
Future Oncology (London, England)|August 17, 2016
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and researchDavid F Penson, Daniel W Lin, Lawrence Karsh, et al.
The American Journal of Managed Care|May 12, 2010
Preliminary treatment considerations among men with newly diagnosed prostate cancerSteven B Zeliadt, Carol M Moinpour, David K Blough, et al.
Cancer|December 17, 2013
Racial variation in the quality of surgical care for bladder cancerDaniel A Barocas, Joann Alvarez, Tatsuki Koyama, et al.
BMC Urology|September 8, 2018
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
BMC Urology|October 5, 2018
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
Pageof 57